XML 71 R61.htm IDEA: XBRL DOCUMENT
v3.25.0.1

License Agreement - Additional Information (Details) - USD ($) $ in Millions |  |  | 1 Months Ended | 3 Months Ended | 12 Months Ended |
--- | --- | --- | --- | --- | --- | ---
Aug. 22, 2023 | Mar. 23, 2020 | Apr. 30, 2024 | Apr. 30, 2019 | Mar. 31, 2025 | Dec. 31, 2024 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2019 | Aug. 31, 2010
License Agreement [Line Items] |  |  |  |  |  |  |  |  |  |
Annual minimum royalty obligations |  |  |  |  |  |  |  |  |  | $ 0.2
Seattle Genetics Agreement |  |  |  |  |  |  |  |  |  |
License Agreement [Line Items] |  |  |  |  |  |  |  |  |  |
Annual license maintenance fees | $ 0.3 |  |  |  |  |  |  |  |  |
Transition Agreement [Member] |  |  |  |  |  |  |  |  |  |
License Agreement [Line Items] |  |  |  |  |  |  |  |  |  |
Termination date |  |  |  |  |  | The Company terminated the Transition Agreement in the first quarter of 2025. |  |  |  |
Astellas Pharma Inc. | Collaboration and License Agreement |  |  |  |  |  |  |  |  |  |
License Agreement [Line Items] |  |  |  |  |  |  |  |  |  |
Sublicense fees |  |  |  |  |  | $ 0.6 | $ 0.2 |  |  |
Upfront payment received |  | $ 80.0 |  |  |  |  |  |  |  |
Astellas Pharma Inc. | Collaboration and License Agreement | Subsequent Event |  |  |  |  |  |  |  |  |  |
License Agreement [Line Items] |  |  |  |  |  |  |  |  |  |
Sublicense fees |  |  |  |  | $ 0.2 |  |  |  |  |
Immuno Gen Inc |  |  |  |  |  |  |  |  |  |
License Agreement [Line Items] |  |  |  |  |  |  |  |  |  |
Milestone payment |  |  | $ 5.0 |  |  |  |  |  |  |
Clinical Development Milestone Payment |  |  | $ 35.0 |  |  |  |  |  |  |
Immuno Gen Inc | Collaborative Arrangement |  |  |  |  |  |  |  |  |  |
License Agreement [Line Items] |  |  |  |  |  |  |  |  |  |
Upfront payment received |  |  |  |  |  |  |  |  | $ 7.5 |
Immuno Gen Inc | Clinical development milestones | Maximum |  |  |  |  |  |  |  |  |  |
License Agreement [Line Items] |  |  |  |  |  |  |  |  |  |
Milestone payment |  |  |  |  |  |  |  |  | 35.0 |
Immuno Gen Inc | Regulatory approval and commercial milestone | Maximum |  |  |  |  |  |  |  |  |  |
License Agreement [Line Items] |  |  |  |  |  |  |  |  |  |
Milestone payment |  |  |  |  |  |  |  |  | $ 320.0 |
UCSB |  |  |  |  |  |  |  |  |  |
License Agreement [Line Items] |  |  |  |  |  |  |  |  |  |
Annual license maintenance fees |  |  |  | $ 0.8 |  |  |  |  |  |
License payment term |  |  |  | 2031 |  |  |  |  |  |
Percentage of remaining maintenance fees outstanding |  |  |  | 50.00% |  |  |  |  |  |
Sublicense fees |  |  |  |  |  | $ 1.6 | $ 1.1 |  |  |
Amgen | Collaboration and License Agreement |  |  |  |  |  |  |  |  |  |
License Agreement [Line Items] |  |  |  |  |  |  |  |  |  |
Sublicense fees |  |  |  |  |  |  |  | $ 0.1 |  |

X
- Definition Annual license maintenance fees + References No definition available. + Details
Name: | ctmx_AnnualLicenseMaintenanceFees
Namespace Prefix: | ctmx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Clinical development milestone payment + References No definition available. + Details
Name: | ctmx_ClinicalDevelopmentMilestonePayment
Namespace Prefix: | ctmx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition License payment term. + References No definition available. + Details
Name: | ctmx_LicensePaymentTerm
Namespace Prefix: | ctmx_
Data Type: | xbrli:gYearItemType
Balance Type: | na
Period Type: | duration

X
- Definition Milestone payment. + References No definition available. + Details
Name: | ctmx_MilestonePayment
Namespace Prefix: | ctmx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage of remaining maintenance fees outstanding. + References No definition available. + Details
Name: | ctmx_PercentageOfRemainingMaintenanceFeesOutstanding
Namespace Prefix: | ctmx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Royalty obligations future minimum payments due. + References No definition available. + Details
Name: | ctmx_RoyaltyObligationsFutureMinimumPaymentsDue
Namespace Prefix: | ctmx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Sublicense fees. + References No definition available. + Details
Name: | ctmx_SublicenseFees
Namespace Prefix: | ctmx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Termination date. + References No definition available. + Details
Name: | ctmx_TerminationDate
Namespace Prefix: | ctmx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Cash received from collaborators during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details
Name: | us-gaap_ProceedsFromCollaborators
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ctmx_SeattleGeneticsAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ctmx_TransitionAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ctmx_AstellasPharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ctmx_CollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ctmx_ImmunoGenIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ctmx_ClinicalDevelopmentMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ctmx_RegulatoryApprovalAndCommercialMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ctmx_UniversityOfCaliforniaSantaBarbaraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ctmx_AmgenAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |